Renal impairment in HIV-1 infected patients receiving antiretroviral regimens including tenofovir in a resource-limited setting

Southeast Asian Journal of Tropical Medicine and Public Health

Volumn 42, Issue 3, 2011, Pages 643-650

  Manosuthi, Weerawat ^a   Prasithsirikul, Wisit ^a   Tantanathip, Preecha ^a   Chimsuntorn, Sukanya ^a   Nilkamhang, Samruay ^a   Sungkanuparph, Somnuek ^b  

^a MINISTRY OF PUBLIC HEALTH   (Thailand)

^b MAHIDOL UNIVERSITY   (Thailand)

Author keywords

HIV; Renal impairment; Tenofovir; Thailand; Toxicity

Indexed keywords

EID: 79961068843     PISSN: 01251562     EISSN: 26975718     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Ananworanich J, Nuesch R, Cote HC, et al. Changes in metabolic toxicity after switching from stavudine/didanosine to tenofovir/lamivudine-a Staccato trial substudyJ Antimicrob Chemother 2008; 61:1340-3. (Pubitemid 351753605)
2. Coca S, Perazella MA. Rapid communication: acute renal failure associated with tenofovir: evidence of drug-induced nephrotoxicityAm J Med Sci 2002; 324: 342-4. (Pubitemid 36109329)
3. Gallant JE, Parish MA, Keruly JC, Moore RD. Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatmentClin Infect Dis 2005; 40:1194-8. (Pubitemid 40490248)
4. Gallant JE, Staszewski S, Pozniak AL. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviralnaive patients: a 3-year randomized trialJAMA 2004; 292:191-201. (Pubitemid 38917996)
5. Gallant JE, Winston JA, DeJesus E, et al. The 3-year renal safety of a tenofovir disoproxil fumarate vs. a thymidine analoguecontaining regimen in antiretroviral-naive patientsAIDS 2008; 22: 2155-63.
6. Gayet-Ageron A, Ananworanich J, Jupimai T, et al. No change in calculated creatinine clearance after tenofovir initiation among Thai patientsJ Antimicrob Chemother 2007; 59:1034-7. (Pubitemid 47073382)
7. Gazzard BG, Anderson J, Babiker A, et al. British HIV Association Guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008. HIVMed 2008; 9: 563-608.
8. Hammer SM, Eron JJ, Jr. Reiss P, et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panelJAMA 2008; 300:555-70.
9. Harris M. Nephrotoxicity associated with antiretroviral therapy in HIV-infected patientsExpert Opin Drug Saf 2008; 7: 389-400.
10. Jao J, Wyatt CM. Antiretroviral medications: adverse effects on the kidneyAdv Chronic Kidney Dis 2010; 17: 72-82.
11. Jones R, Stebbing J, Nelson M, et al. Renal dysfunction with tenofovir disoproxil fumarate-containing highly active antiretroviral therapy regimens is not observed more frequently: a cohort and case-control studyJ Acquir Immune Defic Syndr 2004; 37:1489-95. (Pubitemid 39602339)
12. Keeffe EB, Dieterich DT, Han SH, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 updateClin Gastroenterol Hepatol 2008; 6:1315-41.
13. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study GroupAnn Intern Med 1999; 130: 461-70. (Pubitemid 29135798)
14. Miller DS. Nucleoside phosphonate interactions with multiple organic anion transporters in renal proximal tubuleJ Pharmacol Exp Ther 2001; 299:567-74. (Pubitemid 32979669)
15. Nelson MR, Katlama C, Montaner JS, et al. The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 yearsAIDS 2007; 21:1273-81. (Pubitemid 46883481)
16. Peyriere H, Reynes J, Rouanet I, et al. Renal tubular dysfunction associated with tenofovir therapy: report of 7 casesJ Acquir Immune Defic Syndr 2004; 35: 269-73. (Pubitemid 38280652)
17. Pruvost A, Negredo E, Theodoro F, et al. Pilot pharmacokinetic study of human immunodeficiency virus-infected patients receiving tenofovir disoproxil fumarate TDF: investigation of systemic and intracellular interactions between TDF and abacavir, lamivudine, or lopinavirritonavirAntimicrob Agents Chemother 2009; 53:1937-43.
18. Rho M, Perazella MA. Nephrotoxicity associated with antiretroviral therapy in HIVinfected patientsCurr Drug Saf 2007; 2: 147-54. (Pubitemid 46805547)
19. Rifkin BS, Perazella MA. Tenofovir-associated nephrotoxicity: Fanconi syndrome and renal failureAm J Med 2004; 117: 282-4. (Pubitemid 39092726)
20. Smith KY, Patel P, Fine D, et al. Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ ritonavir forinitial HIV treatmentAIDS 2009; 23:1547-56.
21. Szczech LA, Gupta SK, Habash R, et al. The clinical epidemiology and course of the spectrum of renal diseases associated with HIV infectionKidney Int 2004a; 66: 1145-52. (Pubitemid 39121021)
22. Szczech LA, Hoover DR, Feldman JG, et al. Association between renal disease and outcomes among HIV-infected women receiving or not receiving antiretroviral therapyClin Infect Dis 2004b; 39:1199-206. (Pubitemid 40169320)
23. Zimmermann AE, Pizzoferrato T, Bedford J, Morris A, Hoffman R, Braden G. Tenofovir-associated acute and chronic kidney disease: a case of multiple drug interactionsClin Infect Dis 2006; 42: 283-90. (Pubitemid 43054205)